VIVUS, Inc. (VVUS) Earnings: An Early Look

Page 2 of 2

In VIVUS’ coming report, the big number to look for is full-quarter sales of Qsymia. If the company can draw new patients in and keep existing customers on the drug, then VIVUS will have set itself up as well as possible for the inevitable release of Belviq — which will change the game entirely both for VIVUS and Arena.

The article VIVUS Earnings: An Early Look originally appeared on Fool.com and is written by Dan Caplinger.

Fool contributor Dan Caplinger has no position in any stocks mentioned. You can follow him on Twitter @DanCaplinger. The Motley Fool recommends Express Scripts. The Motley Fool owns shares of Express Scripts.

Copyright © 1995 – 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

Page 2 of 2